Overall Survival of Nonmetastasized NSCLC Patients Treated With Add-On <i>Viscum album</i> L: A Multicenter Real-World Study.

Integr Cancer Ther · 2020 · PMC7457695 · PMID 32856476

Europe PMC DOI

hedged sentences

0.0000

closest p · 0.0× alpha

0.0000

boldest claim

The sentences

highly significantP = 3e-07actually significant

This difference was statistically highly significant (χ 2 = 26.1, P = 3e-07).

also in 132,142 other papers

tendency toward significanceno p-value reported

However, the nonrandomized prospective matched-pair part of this study 38 revealed 52 pairs of stage- and standard oncological treatment-matched NSCLC patients showing 3.08 years of mean survival time in the add-on VA (Iscador) group versus 2.60 years in the control group (no add-on VA; log-rank test: P = .05), showing a tendency toward significance for this outcome and this entity.

also in 340 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.